Assenagon Asset Management S.A. Increases Holdings in Inspire Medical Systems, Inc. $INSP

Key Points

• Assenagon Asset Management increased its Inspire Medical Systems stake by 66.2% in the second quarter, adding 344,221 shares to own 864,395 shares worth approximately $38.6 million. Institutional investors and hedge funds collectively own 94.91% of the company.
• Inspire reported quarterly EPS of $0.14, beating estimates by $0.38, while revenue of $200.6 million exceeded forecasts but declined 7.6% year over year. The company maintained fiscal 2026 EPS guidance of $1.05–$1.45.
• Analyst sentiment remains mixed, with ratings ranging from strong buy to sell; the stock has an overall “Hold” consensus and an average price target of $68, compared with a reported share price of $60.12.

Assenagon Asset Management S.A. increased its position in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 66.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 864,395 shares of the company's stock after acquiring an additional 344,221 shares during the period. Assenagon Asset Management S.A. owned approximately 3.00% of Inspire Medical Systems worth $38,561,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Royal Bank of Canada increased its holdings in Inspire Medical Systems by 16.0% during the 1st quarter. Royal Bank of Canada now owns 32,769 shares of the company's stock valued at $5,220,000 after acquiring an additional 4,528 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Inspire Medical Systems in the first quarter valued at approximately $524,000. Goldman Sachs Group Inc. increased its stake in shares of Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company's stock worth $8,190,000 after purchasing an additional 18,857 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Inspire Medical Systems by 3.8% during the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company's stock worth $2,064,000 after purchasing an additional 577 shares in the last quarter. Finally, Jump Financial LLC acquired a new position in shares of Inspire Medical Systems during the 2nd quarter worth approximately $931,000. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Stock Performance

Shares of NYSE INSP opened at $60.12 on Friday. The firm has a market cap of $1.74 billion, a P/E ratio of 13.01, a price-to-earnings-growth ratio of 4.57 and a beta of 0.70. Inspire Medical Systems, Inc. has a 1 year low of $38.91 and a 1 year high of $147.03. The firm's 50 day moving average price is $47.64 and its 200 day moving average price is $54.51.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The business had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. During the same quarter in the previous year, the business posted $0.45 EPS. The business's quarterly revenue was down 7.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities analysts predict that Inspire Medical Systems, Inc. will post 1.24 EPS for the current year.

Analyst Upgrades and Downgrades

INSP has been the topic of a number of recent research reports. Freedom Capital raised Inspire Medical Systems to a "strong-buy" rating in a research note on Tuesday, June 30th. Royal Bank Of Canada reissued a "sector perform" rating and issued a $60.00 price target on shares of Inspire Medical Systems in a report on Tuesday. Stifel Nicolaus set a $75.00 price objective on Inspire Medical Systems in a research report on Tuesday. UBS Group assumed coverage on Inspire Medical Systems in a research report on Tuesday, July 28th. They issued a "sell" rating and a $39.00 price objective on the stock. Finally, Truist Financial reaffirmed a "hold" rating and set a $62.00 price objective (up from $54.00) on shares of Inspire Medical Systems in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $68.00.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source